Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models

Darolutamide is a novel androgen receptor (AR) antagonist with a distinct chemical structure compared to other AR antagonists and currently in clinical Phase 3 trials for prostate cancer. Using cell‐based transactivation assays, we demonstrate that darolutamide, its diastereomers and its main metabo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Sugawara, Tatsuo, Baumgart, Simon J., Nevedomskaya, Ekaterina, Reichert, Kristin, Steuber, Holger, Lejeune, Pascale, Mumberg, Dominik, Haendler, Bernard
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Molecular Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6766977/
https://ncbi.nlm.nih.gov/pubmed/30828788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32242
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars